WO2026085108A2 - Compositions de lymphocytes b et méthodes d'utilisation - Google Patents

Compositions de lymphocytes b et méthodes d'utilisation

Info

Publication number
WO2026085108A2
WO2026085108A2 PCT/US2025/050889 US2025050889W WO2026085108A2 WO 2026085108 A2 WO2026085108 A2 WO 2026085108A2 US 2025050889 W US2025050889 W US 2025050889W WO 2026085108 A2 WO2026085108 A2 WO 2026085108A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
subject
modified
population
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/050889
Other languages
English (en)
Other versions
WO2026085108A3 (fr
Inventor
Jacob WESLEY
Robert S. SIKORSKI
Riley Scott MCIVOR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immusoft Corp
Original Assignee
Immusoft Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusoft Corp filed Critical Immusoft Corp
Publication of WO2026085108A2 publication Critical patent/WO2026085108A2/fr
Publication of WO2026085108A3 publication Critical patent/WO2026085108A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01076—L-Iduronidase (3.2.1.76)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente divulgation concerne un procédé de réduction des glycosaminoglycanes d'urine (GAG) ou des glycosaminoglycanes (GAG) de liquide cérébro-spinal (CSF) chez un sujet, comprenant : l'administration d'une dose unique d'une population de lymphocytes B modifiés au sujet.
PCT/US2025/050889 2024-10-14 2025-10-14 Compositions de lymphocytes b et méthodes d'utilisation Pending WO2026085108A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463707106P 2024-10-14 2024-10-14
US63/707,106 2024-10-14

Publications (2)

Publication Number Publication Date
WO2026085108A2 true WO2026085108A2 (fr) 2026-04-23
WO2026085108A3 WO2026085108A3 (fr) 2026-05-28

Family

ID=97871845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/050889 Pending WO2026085108A2 (fr) 2024-10-14 2025-10-14 Compositions de lymphocytes b et méthodes d'utilisation

Country Status (1)

Country Link
WO (1) WO2026085108A2 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
US5385582A (en) 1991-02-11 1995-01-31 Ommaya; Ayub K. Spinal fluid driven artificial organ
US20070254842A1 (en) 2006-04-25 2007-11-01 The Regents Of The University Of California Administration of growth factors for the treatment of cns disorders
US20080081064A1 (en) 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
US20090196903A1 (en) 2008-01-29 2009-08-06 Kliman Gilbert H Drug delivery devices, kits and methods therefor
WO2016100932A1 (fr) 2014-12-19 2016-06-23 Immusoft Corporation Lymphocytes b pour l'administration in vivo d'agents thérapeutiques
WO2018201071A1 (fr) 2017-04-27 2018-11-01 Immusoft Corporation Lymphocytes b pour l'administration in vivo d'agents thérapeutiques et doses de ceux-ci

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268110B2 (en) * 2017-01-26 2024-01-01 Sangamo Therapeutics Inc B-cell engineering
JP7891314B2 (ja) * 2020-05-06 2026-07-16 セレクティス ソシエテ アノニム 治療用タンパク質の送達のために細胞を遺伝子改変する方法
WO2022094284A1 (fr) * 2020-10-30 2022-05-05 Immusoft Corporation Méthodes d'administration de lymphocytes b génétiquement modifiés pour l'administration in vivo d'agents thérapeutiques

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
US5385582A (en) 1991-02-11 1995-01-31 Ommaya; Ayub K. Spinal fluid driven artificial organ
US20070254842A1 (en) 2006-04-25 2007-11-01 The Regents Of The University Of California Administration of growth factors for the treatment of cns disorders
US20080081064A1 (en) 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
US20090196903A1 (en) 2008-01-29 2009-08-06 Kliman Gilbert H Drug delivery devices, kits and methods therefor
WO2016100932A1 (fr) 2014-12-19 2016-06-23 Immusoft Corporation Lymphocytes b pour l'administration in vivo d'agents thérapeutiques
US20230081163A1 (en) 2014-12-19 2023-03-16 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
WO2018201071A1 (fr) 2017-04-27 2018-11-01 Immusoft Corporation Lymphocytes b pour l'administration in vivo d'agents thérapeutiques et doses de ceux-ci

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Animal Cell Culture", 1986
"DNA Cloning: A Practical Approach", vol. 1, 2, 1984
"Nucleic Acid Hybridization", 1985
"Nucleic Acid Hybridization: Modern Applications", 2009
"Oligonucleotide Synthesis: Methods and Applications", 2004
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
B. PERBAL: "Practical Guide to Molecular Cloning", 2010
FRESHNEY, R.I.: "RNA Methodologies: A Laboratory Guide for Isolation and Characterization", 2005, JOHN WILEY & SONS
JIN ZMAITI SHULS H ET AL.: "The hyperactive Sleeping Beauty transposase SB 100X improves the genetic modification of T cells to express a chimeric antigen receptor", GENE THER, vol. 18, no. 9, 2011, pages 849 - 856
SAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2000

Also Published As

Publication number Publication date
WO2026085108A3 (fr) 2026-05-28

Similar Documents

Publication Publication Date Title
TWI357336B (en) Uses of il-23 agonists and antagonists; related re
US11000572B2 (en) Composition having tissue-repairing activity, and use therefor
JP6948250B2 (ja) Ｌａｒファミリーホスファターゼの活性を阻害する組成物及び方法
EA005005B1 (ru) ГИБРИДНЫЙ ПОЛИПЕПТИД β1α-ИНТЕРФЕРОНА ЧЕЛОВЕКА, ЕГО МУТАНТНЫЕ ФОРМЫ И ПРОИЗВОДНЫЕ И СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
KR101535791B1 (ko) 개량형 이듀로네이트-2-설파타제 및 이의 용도
WO2005025606A1 (fr) Erythropoietines a action prolongee pouvant maintenir une activite de protection tissulaire d'une erythropoietine endogene
US20190161535A1 (en) Compositions and methods for treating spinal muscular atrophy
HK1200489A1 (en) Recombinant human naglu protein and uses thereof
US20050037004A1 (en) Treatment of chronic joint inflammation
EP3571298B1 (fr) Traitement de la maladie de krabbe par transplantation de sang de cordon ombilical (tsco) et expression accrue de la galactocérébrosidase (galc)
US20050176627A1 (en) Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
Radtke et al. Palifermin (Kepivance™) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support
WO1997003691A1 (fr) Methode de traitement de maladies neurologiques au moyen d'antagonistes d'interferons
Strisciuglio et al. Variable clinical presentation of carbonic anhydrase deficiency: evidence for heterogeneity?
MXPA05002617A (es) Eritropoyetinas de accion prolongada que mantienen la actividad protectora de tejidos de la eritropoyetina endogena.
US12357700B2 (en) Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents
Pochon et al. Gene Therapy for Amyotrophic Lateral Sclerosis (ALS) Using a Polymer Encapsulated Xenogenic Cell Line Engineered to Secrete hCNTF. Lausanne University Medical School, Lausanne, Switzerland
ES2220704T3 (es) Utilizacion de interferon alfa en el tratamiento del sarcoma de ewing.
ES2285755T3 (es) Material biologico para el tratamiento de un mamifero por transferencia de genes de anticuerpos y composicion farmaceutica que lo contiene.
RU2837724C2 (ru) Способ комбинаторной терапии при лечении миелопролиферативных новообразований конъюгатом дифтерийного токсина с интерлейкином-3 человека в комбинации с другими агентами
Lloris American Society for Gene and Cell Therapy (ASGCT)-18th Annual Meeting. New Orleans, Louisiana, USA-May 13-16, 2015
TW202045202A (zh) 用於治療肺纖維化和肺氣腫的組合物及其使用方法
HK40005250A (en) Compositions and methods for treating spinal muscular atrophy
HK1212888B (en) Novel method for treating spinal cord injury using hmgb1 fragment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25812186

Country of ref document: EP

Kind code of ref document: A2